Tecentriq is an immunotherapy drug that stimulates the body’s immune system to detect and attack cancer cells.
Patients with or without a tumor protein called PD-L1, which typically makes people more receptive to immunotherapy treatments, can use Tecentriq, according to Reuters.
The FDA based the approval on the results of a recent late-stage clinical trial showing patients taking Tecentriq lived, on average, 4.2 months longer than those treated with chemotherapy.
More articles on supply chain:
Tenn. high school opens medical device machinery lab
Sen. Blumenthal urges DOJ to reject Mylan settlement
TPC names ROi preferred supply chain partner: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.